
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience's commitment to precision neuropsychiatry is underscored by its robust pipeline, featuring several clinical-stage assets, including ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300, which are aimed at treating psychiatric disorders through biomarker-guided approaches. The company boasts a strong cash position of approximately $275 million, enabling it to effectively advance its clinical programs and sustain operations. Promising clinical outcomes, such as significantly improved MADRS scores in ALTO-207 trials and positive EEG measure trends, further reinforce the potential for successful therapeutic interventions and a solid growth trajectory in the field of personalized psychiatry.
Bears say
Alto Neuroscience faces significant challenges affecting its financial outlook, primarily due to the disappointing results from its Phase 2 proof-of-concept trial for ALTO-101, which failed to achieve statistical significance on key endpoints. The inherent high failure rates associated with clinical trials for depression, attributed to patient heterogeneity and elevated placebo responses, further complicate the company's ability to successfully bring its products to market. Additionally, there is a looming risk concerning the protection of the company's intellectual property; any potential issues regarding patents could compromise asset value and lead to negative revisions of the company's overall valuation.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares